Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC

This study is testing an enhanced CAR-T cell therapy — a treatment that uses your own immune cells, genetically engineered to target a protein called PSMA found on prostate cancer cells — for men with advanced prostate cancer that has stopped responding to standard treatments. **You may be eligible if...** - You are a man between 18 and 75 with metastatic castration-resistant prostate adenocarcinoma (CRPC) - Your cancer has progressed on standard CRPC treatments (such as new hormone therapies, chemotherapy, or radium-223) - Your tumor biopsy shows positive PSMA expression - Your expected survival is more than 6 months - Your overall health is acceptable (ECOG score less than 2) **You may NOT be eligible if...** - Your tumor does not express PSMA - You have severe infections, autoimmune disease, or other serious health problems - Your organ function does not meet required thresholds - You have not yet progressed on standard CRPC treatments Talk to your doctor to see if this trial is right for you.